Recently, Alibaba Health Pharmacy has drawn public attention over allegations of violating China’s Advertising Law. According to media reports, some of its online advertisements for pharmaceuticals and medical devices allegedly contained exaggerated claims about efficacy, used absolute language (such as ‘most effective’ or ‘100% cure’), and failed to clearly disclose contraindications and potential side effects—practices prohibited under Article 16 of the Advertising Law. This article explicitly bans medical, pharmaceutical, and medical device ads from making definitive statements or guarantees regarding safety or effectiveness, as well as citing cure or success rates. Regulatory authorities have launched an investigation into these allegations. If violations are confirmed, Alibaba Health could face penalties including fines, mandatory ad removals, or even temporary suspension of related business operations. As a leading player in China’s digital healthcare sector, Alibaba Health is expected to set a compliance benchmark. This incident serves as a reminder to the entire industry to rigorously review advertising content and strictly adhere to legal requirements to protect consumer rights and ensure medication safety.
近日，阿里健康大药房因涉嫌违反《中华人民共和国广告法》引发关注。据媒体报道，其在部分线上平台发布的药品或医疗器械广告中，存在夸大疗效、使用绝对化用语（如“最有效”“100%治愈”等）以及未显著标明禁忌症和不良反应等违规行为。根据《广告法》第十六条，医疗、药品、医疗器械广告不得含有表示功效、安全性的断言或保证，也不得说明治愈率或有效率。监管部门已对相关线索展开调查，若查实违规，阿里健康可能面临罚款、下架广告甚至暂停相关业务的处罚。作为互联网医药领域的头部企业，阿里健康被寄予合规经营的示范作用，此次事件也提醒整个行业需加强广告内容审核，严格遵守法律法规，保障消费者知情权与用药安全。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/20155.html